With its unique technology, nuclear medicine shows more practical and imaginative space for clinical application in the field of diagnosis and treatment. At the same time, strong professionalism, high dependence on upstream and downstream industries, and the need to break through policies and talent supply have built barriers to the nuclear medicine industry. The clinical needs are there, and the radionuclide technology is eager to try. Where is the incision? How to advance?
Recently, nuclear drugs have made continuous progress.
In November, Chengdu Nurit and Nanjing Anji Bio jointly signed the Strategic Cooperation Agreement on the Development of Peptide-Coupled Radionuclide Innovative Drugs (PRC), reaching a cooperative project development of more than 100 million yuan; Shanghai Fulian acquired US Focus-X for US$ 245 million, and reached a cross-border transaction of nuclear drugs and peptides.
Nuclear medicine ushered in more cross-disciplinary participants and gradually broke through the niche track.
Xiantong Medicine is one of the earliest pioneers in China to transform into innovative nuclear drugs. Its diagnostic nuclear drugs targeting A amyloid β-protein have been declared NDA and are expected to be approved next year, which will make up for the gap in the diagnosis of AD nuclear drugs in China. At the same time, as the first peptide receptor radionuclide therapy (PRRT) drug in China, XTR008 has entered the phase III clinic. Behind these achievements, what kind of trade-offs and barriers has Xiantong Medicine experienced? This is not only a milestone of the enterprise, but also a microcosm of the development of the industry.
On December 27th (Tuesday), from 20: 00 to 21: 30, Arterial New Medicine and Xiantong Medicine held an online Panel, inviting experts from clinical, investment and upstream and downstream industries to discuss the advantages and promote thinking of nuclear medicine in the field of diagnosis and treatment from the perspectives of nuclear medicine research and development, clinical trials, application and registration, and track development, with a view to contributing to industrial development.
Live broadcast platform [artery new medicine video number], make an appointment before the text.
Add a small assistant WeChat, ask a question you care about, and join the nuclear medicine exchange group.
Guest introduction
Liu Chuanwen
Managing Director of Xinjun Capital
Responsible for mergers and acquisitions and equity investment of medical industry projects. Previously, he served as general manager of Guangdong Junqi Pharmaceutical Technology Co., Ltd., deputy general manager of Shanghai Jielong Biological Products Co., Ltd. and senior investment manager of Yutong Group Investment Department.
Wu Haowei
Midu biology CEO
Master of Pharmaceutical Engineering and Science, University of Leeds, UK, has more than ten years of experience in innovative drug research and development and CRO operation, and has participated in the pre-clinical and clinical research design of dozens of innovative drugs, including several radioactive drugs. At present, he has led the team to obtain domestic clinical trial approval documents for six radiopharmaceuticals, including three innovative drugs of Class 1.1, among which he completed the first domestic original research and localization study of 18F radiopharmaceuticals as the main person in charge and participated in the organization of the first domestic clinical phase III study of 18F radiopharmaceuticals.
Peng Wang
Vice president of xiantong medicine
Mainly responsible for new drug research and development, project management, registration and other affairs. He has 14 years working experience in CFDA and CDE, participated in the research and establishment of some drug registration policies, and is familiar with the laws, regulations and policy direction of drug supervision in China. Among them, he has 7 years of experience in CDE drug technical evaluation, writes more than 300 evaluation reports every year, and is familiar with the relevant laws and regulations and guiding principles of drug research and development and evaluation; 5 years of comprehensive management experience in CDE, responsible for the comprehensive management and coordination of CDE internal review, and participating in the research and formulation of CDE main management norms. In 2012-2013, he was a visiting scholar at the Center for Translational Medicine of the University of Maryland, Baltimore, USA. He joined Xiantong Medicine in 2016 and has more than 6 years of experience in the research and development management of radiopharmaceuticals, and is familiar with the research and development progress of radiopharmaceuticals at home and abroad.
Xu bailing
Xiantong medical diagnostic products CMO
Columbia University, Missouri-Visiting Professor; Yangming University, Taiwan Province-Adjunct Professor; American Journal of Nuclear Cardiology-Editorial Board; Member of the American Nuclear Cardiology Association-International Expert Advisory Committee. An expert in nuclear cardiology has witnessed and participated in the whole development of nuclear cardiology in the United States. The main research directions include: the clinical application of new imaging technologies such as SPECT myocardial blood flow quantification, PET myocardial blood flow quantification and PET myocardial metabolism quantification, and the clinical trials of innovative PET imaging agents. At present, he is the Chief Medical Officer (CMO) of diagnostic products of Xiantong International Pharmaceutical Technology Co., Ltd. (Xiantong Pharmaceutical), and is the chief person in charge of clinical trials of two new cardiovascular PET imaging agents and two new cranial nerve PET imaging agents.
Enterprise introduction
About Xinjun Capital Hi-Tech Xinjun was established in 2015, led by Nanjing Hi-Tech (600064) as a limited partner. The management team comes from domestic first-class investment and investment banking institutions, and has profound knowledge and rich resources in venture capital and capital markets. Xinjun focuses on the equity investment of growth enterprises, with great health and high technology as the main investment direction. Xinjun helps enterprises to build a growing resource ecology through an international investment vision and investment management model. Some investment cases in the field of medical health: Baipusisi, Master Bio, Alice, Hualan, Rendu Bio, Chengdu Nurit, Yimai Sunshine, Dakang Medical, Zhengya Dentistry, etc.
About Mido Bio-Mido (Nanjing) Biotechnology Co., Ltd. was established in 2012. As a domestic molecular imaging medicine R&D outsourcing (MI-CRO) enterprise, Mido Bio can provide customers at home and abroad with overall solutions and outsourcing technical services for new drug research and development, such as drug screening, biological distribution, pharmacokinetics research and pharmacodynamic evaluation. The business includes transformation research from naked (small) mice, rats and monkeys to human bodies. Focus on major diseases such as tumor, cardiovascular and cerebrovascular diseases, Alzheimer’s disease, Parkinson’s disease, epilepsy, rheumatic immunity, diabetes, NASH and other frontier research fields, explore disease mechanisms, develop diagnostic and therapeutic drugs, and evaluate therapeutic effects. At the same time, Mido Bio provides one-stop services from early development, CMC, preclinical, clinical and registration declaration for radiopharmaceuticals, and has obtained domestic clinical trial approvals for several projects.
Organizer introduction
About Xiantong Medicine Beijing Xiantong International Pharmaceutical Technology Co., Ltd. is an innovative nuclear medicine leading enterprise rooted in China and facing the global development. In 2014, it officially launched the research and development of a new generation of radiopharmaceuticals. It is headquartered in Beijing, and has modern intelligent production bases for radiopharmaceuticals in Jiangsu, Guangdong and Sichuan. The United States has branches and has formed business cooperation with more than a dozen multinational pharmaceutical companies. Relying on the world’s leading R&D resources for accurate diagnosis and treatment of radiopharmaceuticals, Xiantong has taken the lead in deploying a variety of targeted therapy and accurate diagnosis radiopharmaceuticals in the fields of tumors, neurodegenerative diseases and cardiovascular diseases, and has conducted or completed clinical trials respectively, and will be listed in the next few years. Since April 2020, Xiantong Pharmaceutical has successfully raised nearly RMB 1 billion, which has won the favor of major investment institutions and plans to land in major capital markets in the near future.
About new arterial medicine
Arterial New Medicine is a media research platform of Arterial Network, which focuses on biomedicine, and provides "deep" and "incremental" communication value for innovative entrepreneurs from two dimensions: content and operation. In terms of content, there are mainly financing launch, enterprise interview, "drug maker" column, industry in-depth interpretation, track report, etc. In terms of operation, through the brand column of "VB Sixianghui", we focus on practical problems, discuss industrial trends, and promote practical cooperation through ideological collision.
Special achievements: [Interpretation of IPO- Financial Report] [iPSC] [Nuclear Medicine] [Protein Degradation Agent] [Upstream Tool] [Synthetic Biology] [Organ-like and Organ Chip] [VB Conference] and so on.
About VB Sixianghui
VB Sixiang Club is one of the brand activities of Arterial Network. It is a face-to-face platform with the core of discussing solutions in the field of medicine and health, aiming at "focusing on practical problems and discussing industrial trends". Focusing on the development status of the core theme, the activity conducted in-depth discussion, analysis and collision on the difficulties, pain points and obstacles encountered. At the same time, we should deeply understand the resource endowment between enterprises and promote practical cooperation with ideological collision. "Each issue, one theme, one carrier, one ecology".